Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 48.

https://doi.org/10.1182/blood.V120.21.48.48

Published: 2012

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD

Blood (2012) 120 (21): 673.

https://doi.org/10.1182/blood.V120.21.673.673

Published: 2012

Journal Articles

Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220

Christoph Schaab, Dr., Felix Oppermann, Dr., Heike Pfeifer, Dr. med., Martin Klammer, Dr., Andreas Tebbe, Dr., Thomas Oellerich, Dr. med., Jürgen Krauter, Prof. Dr. med., Mark J. Levis, MD, PhD, Alexander E Perl, MD, Henrik Daub, Dr., Björn Steffen, MD, Klaus Godl, Dr., Hubert Serve, Prof. Dr. med.

Blood (2012) 120 (21): 786.

https://doi.org/10.1182/blood.V120.21.786.786

Published: 2012

Journal Articles

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Blood (2010) 116 (21): 333.

https://doi.org/10.1182/blood.V116.21.333.333

Published: 2010

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

Journal Articles

Distinct Expression Patterns of Human microRNAs in Myeloid Differentiation and Acute Myeloid Leukemia.

Fabienne Isken, Björn Steffen, Birgit Markus, Claudia Hömme, David Kosel, Thomas Illmer, Sylvia Merk, Martin Dugas, Wolfgang E. Berdel, Hubert Serve, Carsten Müller-Tidow

Blood (2006) 108 (11): 2231.

https://doi.org/10.1182/blood.V108.11.2231.2231

Published: 2006

Journal Articles

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction

Lara Tickenbrock, Joachim Schwäble, Markus Wiedehage, Björn Steffen, Bülent Sargin, Chunaram Choudhary, Christian Brandts, Wolfgang E. Berdel, Carsten Müller-Tidow, Hubert Serve

Blood (2005) 105 (9): 3699–3706.

https://doi.org/10.1182/blood-2004-07-2924

Published: 2005

Journal Articles

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

Masao Mizuki, Joachim Schwäble, Claudia Steur, Chunaram Choudhary, Shuchi Agrawal, Bülent Sargin, Björn Steffen, Itaru Matsumura, Yuzuru Kanakura, Frank D. Böhmer, Carsten Müller-Tidow, Wolfgang E. Berdel, Hubert Serve

Blood (2003) 101 (8): 3164–3173.

https://doi.org/10.1182/blood-2002-06-1677

Published: 2003

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Distinct Expression Patterns of Human microRNAs in Myeloid Differentiation and Acute Myeloid Leukemia.

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only